Neuromyelitis Optic Spectrum Disorder Drugs Market

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis Optic Spectrum Disorder Drugs Market contains market size and forecasts of Neuromyelitis Optic Spectrum Disorder Drugs in global, including the following market information:

Global Neuromyelitis Optic Spectrum Disorder Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Neuromyelitis Optic Spectrum Disorder Drugs Market Sales, 2017-2022, 2023-2028, (Kiloton)

Global top five Neuromyelitis Optic Spectrum Disorder Drugs companies in 2021 (%)

The global Neuromyelitis Optic Spectrum Disorder Drugs market was valued at 48 million in 2021 and is projected to reach US$ 59 million by 2028, at a CAGR of 2.8% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Glucocorticoids Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neuromyelitis Optic Spectrum Disorder Drugs include Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork and Baxter, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Neuromyelitis Optic Spectrum Disorder Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neuromyelitis Optic Spectrum Disorder Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Kiloton)

Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, by Type, 2021 (%)

Glucocorticoids

Immunotherapies

Other

Global Neuromyelitis Optic Spectrum Disorder Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Kiloton)

Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, by Application, 2021 (%)

Acute Attack

Remission Prophylactic Treatment

Global Neuromyelitis Optic Spectrum Disorder Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Kiloton)

Global Neuromyelitis Optic Spectrum Disorder Drugs Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neuromyelitis Optic Spectrum Disorder Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Neuromyelitis Optic Spectrum Disorder Drugs revenues share in global market, 2021 (%)

Key companies Neuromyelitis Optic Spectrum Disorder Drugs sales in global market, 2017-2022 (Estimated), (Kiloton)

Key companies Neuromyelitis Optic Spectrum Disorder Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP